Medicare Enrollment for Providers No Longer Required Under Medicare Parts C and D

11 April 2018 Health Care Law Today Blog
Authors: Alexis Finkelberg Bortniker

On April 2, 2018, CMS released the Contract Year 2019 Final Rules for Medicare Advantage (MA) and Part D (the MA Final Rule), incorporating changes that support CMS’ stated commitment to supporting flexibility and efficiency throughout the MA and Part D Programs.

The MA Final Rule incorporates broad changes to several aspects of the MA program, including changes to the marketing rules, the star rating process and benefit uniformity requirements, among others. Of note to providers, and the subject of today’s post, the MA Final Rule has also eliminated the requirement that providers and suppliers contracting with MA Plans, and prescribers prescribing drugs covered by Part D programs, be enrolled in Medicare. Instead, CMS will rely upon a “Preclusion List,” as described below, to eliminate prescribers, providers, and suppliers who are ineligible to provide items or services under these programs.

New Rule Eliminates Medicare Enrollment Requirement

In May of 2014, CMS implemented a rule that required that prescriptions for covered Part D drugs be prescribed by prescribers enrolled in Medicare. Later, in November of 2016, CMS implemented a rule that required providers and suppliers that furnished health care items or services to MA plan members to be enrolled in Medicare by 2019. Under the MA Final Rule, CMS is eliminating this requirement. The text of the new regulations, to take effect January 1, 2019, will instead (i) prohibit MA Plans from paying for services provided by providers and suppliers who are included in a “Preclusion List” and (ii) require pharmacy benefit managers to reject a pharmacy claim for a Part D drug if the individual who prescribed the drug is included on the preclusion list. The “Preclusion List” will be compiled by CMS and will include providers and suppliers (i) that are currently revoked from Medicare or who have engaged in behavior for which CMS could have revoked the provider or supplier to the extent applicable if they had been enrolled in Medicare, and (ii) whose underlying conduct CMS determines is detrimental to the best interests of the Medicare program. The Preclusion List will be separate and distinct from the OIG Exclusion List.

CMS will make the Preclusion List available to MA plans and Part D plan sponsors, who will be required to deny payment for claims submitted by, or associated with prescriptions written by, prescribers and providers on the list.

Impact of the New Rule on Providers and Suppliers

This new requirement allows flexibility to prescribers, providers and suppliers who have not enrolled in Medicare to provide services to MA plan members, easing the burden of enrollment, and allowing providers who have opted out of providing services under traditional Medicare to provide services to beneficiaries under Medicare part C or prescribe Part D covered drugs.

Stay tuned as subsequent posts will cover additional changes as a result of the MA Final Rule.

For more information about Foley’s Health Care Practice including the team, publications, and other materials, visit www.foley.com/health-care.

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.

Related Services

Insights

Text Messages, EDiscovery, and the New Threat to Privacy
21 November 2019
CMS Proposes Enhanced Scrutiny over Medicaid Supplemental Payments
20 November 2019
Health Care Law Today
The Purpose of a Corporation
November 2019
Legal News: Business Law
Should This Be a "Mobility" Industry Blog?
19 November 2019
Dashboard Insights
PATH Summit 2019
18-20 December 2019
Arlington, VA
Madison CLE Days
18-19 December 2019
Madison, WI
MedTech Impact Expo & Conference
13-15 December 2019
Las Vegas, NV
HFMA MA-RI Annual Compliance Update
12 December 2019
Boston, MA